SCHEMBL1383658

SCHEMBL1383658

[CH](Cc1ccccc1)c1ccco1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
G6PC1 P35575 1/20 0.50
ALDH1A1 P00352 11/20 0.46
MAPT P10636 9/20 0.46
LMNA P02545 4/20 0.46
MAPK1 P28482 2/20 0.46
POLB P06746 8/20 0.46
KMT2A Q03164 7/20 0.46
MEN1 O00255 6/20 0.46
RECQL P46063 4/20 0.46
HSD17B10 Q99714 3/20 0.46
TSHR P16473 2/20 0.46
ALOX15 P16050 2/20 0.46
ALOX12 P18054 2/20 0.46
HTT P42858 2/20 0.46
APEX1 P27695 1/20 0.46
MAOB P27338 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
KDM4E B2RXH2 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
BLM P54132 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6569729 0.84 GPR52 (0.50) G6PC1ALDH1A1MAPTLMNAMAPK1
SCHEMBL8091560 0.77 ALDH1A1 (0.46) G6PC1ALDH1A1MAPTLMNAMAPK1
SCHEMBL8146531 0.77 ALDH1A1 (0.46) G6PC1ALDH1A1MAPTLMNAMAPK1
SCHEMBL11194309 0.76 ALDH1A1 (0.38) G6PC1ALDH1A1MAPTLMNAMAPK1
SCHEMBL4274935 0.73 SIRT1 (0.41) ALDH1A1MAPTMAPK1POLBTSHR
SCHEMBL10981074 0.73 G6PC1 (0.53) G6PC1ALDH1A1MAPTLMNAMAPK1
SCHEMBL270295 0.73
SCHEMBL9040309 0.72 ALDH1A1 (0.51) ALDH1A1MAPTLMNAPOLBKMT2A
SCHEMBL10431713 0.71
SCHEMBL183492 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4818110-B2 2011-11-16 JP claimed
EP-1651621-B1 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2008-08-06 EP claimed
US-7304051-B2 Quinoxaline compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-04 US claimed
US-7241759-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-10 US claimed
EP-1651621-A1 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-03 EP claimed
WO-2005016896-A1 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-24 WO claimed
US-20050038032-A1 Quinoxaline compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-17 US claimed
CN-117957278-A Polymer compositions stabilized with organic disulfide blends 阿科玛股份有限公司 2024-04-30 CN disclosed
CN-117320553-A Herbicide/safener combinations based on substituted [ (1,5-diphenyl-1H-1,2,4-triazol-3-yl) oxy ] acetic acid and its salt safeners 拜耳公司 2023-12-29 CN disclosed
US-7947833-B2 methods that are useful in the preparation of amidophenyl-sulfonylamino-quinoxaline compounds CCK2 modulators are disclosed by sulfonylation JANSSEN PHARMACEUTICA NV (BE) 2011-05-24 US disclosed
US-7563895-B2 Quinoxaline compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2009-07-21 US disclosed
US-7495037-B2 Dental coating materials IVOCLAR VIVADENT AG (LI) 2009-02-24 US disclosed
EP-1651621-B1 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2008-08-06 EP disclosed
EP-0317259-A3 HETEROCYCLIC INSECTICIDES ICI AMERICAS INC. (US) 1990-10-17 EP disclosed
CN-1033622-A HETEROCYCLIC INSECTICIDES ICI AMERICA INC (US) 1989-07-05 CN disclosed
CN-1033622-A HETEROCYCLIC INSECTICIDES ICI AMERICA INC (US) 1989-07-05 CN disclosed
EP-0317265-A2 Novel imidate insecticides ZENECA INC. (US) 1989-05-24 EP disclosed
EP-0317265-A2 Novel imidate insecticides ZENECA INC. (US) 1989-05-24 EP disclosed
EP-0317259-A2 Heterocyclic insecticides ICI AMERICAS INC. (US) 1989-05-24 EP disclosed
US-4064239-A LIVER FLUKES MERCK & CO., INC. (US) 1977-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038032-A1 Quinoxaline compounds CCKAR, CCKBR, GIPR G6PC1 241/4885ALDH1A1 4427/4885MAPT 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.